Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer

Trilostane and aminoglutethimide, both given with a physiological replacement dose of hydrocortisone, were randomly allocated to 112 eligible patients with postmenopausal advanced breast cancer. Following treatment failure on either drug the patient continued with the other, if they were in a suitab...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oncology (Royal College of Radiologists (Great Britain)) 1995, Vol.7 (2), p.87-92
Main Authors: Williams, C.J., Barley, V.L., Blackledge, G.R., Rowland, C.G., Tyrrell, C.J., Bachelot, F., Dermaille, A., Fargeot, P., Namer, M., Pouillart, J., Serin, D.
Format: Article
Language:English
Subjects:
Administration, Oral
Adverse effects
Aged
Aminoglutethimide
Aminoglutethimide - administration & dosage
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Breast neoplasm
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Chemotherapy
Clinical trial
cross-over
Cross-Over Studies
Dihydrotestosterone - administration & dosage
Dihydrotestosterone - analogs & derivatives
Drug Administration Schedule
Female
Humans
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Postmenopausal
Postmenopause
Treatment Outcome
Trilostane
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trilostane and aminoglutethimide, both given with a physiological replacement dose of hydrocortisone, were randomly allocated to 112 eligible patients with postmenopausal advanced breast cancer. Following treatment failure on either drug the patient continued with the other, if they were in a suitable clinical condition. Sixty-three patients initially received trilostane, of whom 33 subsequently received aminoglutethimide; 49 patients initially had aminoglutethimide and 14 of these then received trilostane. Both groups of patients were comparable in all respects. There was no difference in the response rate to either drug or in the average time to disease progression for the two drugs. Of the 47 patients who received both drugs, nine (19%) showed a response to both, indicating no cross-resistance. Side effects were seen to both drugs in approximately half the patients; these were mainly gastrointestinal symptoms with trilostane and rashes and drowsiness with aminoglutethimide. There was no evidence of cross-over patient susceptibility to side effects.
ISSN:0936-6555
1433-2981
DOI:10.1016/S0936-6555(05)80807-6